Aurinia Sinks After FDA Official Questions Its Drug in Post (2)

Aurinia Pharmaceuticals Inc. slumped Monday after a top Food and Drug Administration official wrote and then deleted a post saying the company’s approved medicine for an immune disorder has “significant toxicity” and hasn’t been shown to help patients.

In a LinkedIn post that was subsequently removed, George Tidmarsh criticized the FDA’s 2021 approval of voclosporin, which is marketed under the name Lupkynis and used to treat lupus nephritis, a disorder that causes the body’s immune system to damage the kidneys. Tidmarsh later clarified that his earlier post reflected “my own personal views” and not those of the agency.

Aurinia ...